Lista de obras -

Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience.

artículo científico publicado en 2011

Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

scientific article published on 07 September 2018

Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?

artículo científico publicado en 2017

Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease

artículo científico publicado en 2017

Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study

scientific article published on 22 March 2020

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

artículo científico publicado en 2020

Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study

scientific article published on 26 October 2020

Editorial: biologics in the therapy of Crohn's disease-the fog clears

artículo científico publicado en 2020

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease.

artículo científico publicado en 2018

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

scientific article published on 14 April 2020

Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis

scientific article published on 10 September 2018

Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.

artículo científico publicado en 2015

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis

scientific article published on 13 June 2019

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.

artículo científico publicado en 2017

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease

artículo científico

Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID

artículo científico publicado en 2020

Letter: should we intensify infliximab in acute severe ulcerative colitis?

artículo científico publicado en 2020

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

artículo científico publicado en 2018

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis

artículo científico publicado en 2015

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

artículo científico publicado en 2019

Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease

artículo científico publicado en 2018

Reply

artículo científico publicado en 2018

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer

Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

scientific article published on 02 August 2018

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study

artículo científico publicado en 2020

Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis

scientific article published on 10 July 2018

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.

artículo científico publicado en 2015

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response

artículo científico publicado en 2019

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

artículo científico publicado en 2019

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study

artículo científico publicado en 2019

Lista de obras de

Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience.

Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?

Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease

Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study

Editorial: biologics in the therapy of Crohn's disease-the fog clears

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease.

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis

Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.

Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease

Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID

Letter: should we intensify infliximab in acute severe ulcerative colitis?

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial

Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease

Reply

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer

Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study

Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study